Sign In
Buy NYXH
$2.87
-0.100 (-3.37%)
At Close: Jun 03, 2026
Nyxoah S.A. Being Investigated on Behalf of Nyxoah S.A.
02:45pm, Monday, 31'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Nyxoah S.A. ("Nyxoah S.A.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
02:10pm, Monday, 31'st Mar 2025
NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH).
Nyxoah S.A. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - NYXH
07:25am, Monday, 31'st Mar 2025
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Nyxoah S.A. ("Nyxoah S.A.
Nyxoah S.A. Being Investigated on Behalf of Nyxoah S.A.
03:00pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Nyxoah S.A. ("Nyxoah S.A.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
12:00pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH).
FDA Issues Nyxoah an Approvable Letter for its Genio® System
03:00am, Wednesday, 26'th Mar 2025
INSIDE INFORMATION REGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Br
Nyxoah SA (NYXH) Q4 2024 Earnings Call Transcript
04:45pm, Thursday, 13'th Mar 2025
Nyxoah SA (NASDAQ:NYXH ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO Conference Call Participants Adam M
Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates
08:15am, Thursday, 13'th Mar 2025
Nyxoah SA (NYXH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.41 per share a year ago.
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results
02:00am, Thursday, 13'th Mar 2025
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 202 4 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in Ma
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
05:05pm, Monday, 10'th Mar 2025
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
04:30pm, Monday, 03'rd Mar 2025
Nyxoah to Participate in the Oppenheimer 35 th Annual Healthcare MedTech & Services Conference
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East
01:05am, Wednesday, 19'th Feb 2025
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates
Publication relating to transparency notifications
04:30pm, Monday, 20'th Jan 2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), January 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 M
Nyxoah: The Future Of OSA
04:01am, Monday, 30'th Dec 2024
Nyxoah's Genio implant is poised to revolutionize Obstructive Sleep Apnea treatment, with FDA approval expected in Q1 2025 acting as a potential catalyst for shares. Nyxoah, founded by Robert Taub, is
Publication relating to transparency notifications
04:30pm, Friday, 20'th Dec 2024
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 20, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2
